Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches

Osteogenesis imperfecta (OI) is an inherited skeletal disorder that leads to bone fragility and multiple fractures. Given advances in the genetic understanding of existing phenotypes and newly discovered mutations, therapeutic management of OI has become challenging. Denosumab, a monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Majdoub, Fatma, Ferjani, Hanene Lassoued, Nessib, Dorra Ben, Kaffel, Dhia, Maatallah, Kaouther, Hamdi, Wafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Pediatric Endocrinology 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329944/
https://www.ncbi.nlm.nih.gov/pubmed/37401056
http://dx.doi.org/10.6065/apem.2346058.029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329944/
https://www.ncbi.nlm.nih.gov/pubmed/37401056
http://dx.doi.org/10.6065/apem.2346058.029

Ejemplares similares